Q: Today, Acasti (APO) announced positive feedback from the US FDA and, as a result, its shares jumped about 50%. However, the share price of NTP, which owns almost 50% of APO, rose less than 10%. I would have expected an approx. 25% increase for NTP. Is this a good arbitrage opportunity?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: At this time, the only healthcare stock I hold is a 3% weighting in CXR. I would like to add to this sector. My question is, after today's developments with Valeant, would you recommend initiating a small position? Any other suggestions are most welcome.
Thank you
Thank you
Q: Hi Peter and Team,
Considering Valiant's announced deal with Walgreens today, what is the Team's assessment of VRX going forward? I am currently up 10% on the stock and I am thinking of letting it ride for now. Your comments will be greatly appreciated.
Harry
Considering Valiant's announced deal with Walgreens today, what is the Team's assessment of VRX going forward? I am currently up 10% on the stock and I am thinking of letting it ride for now. Your comments will be greatly appreciated.
Harry
Q: This sector is incredibly exciting. What's your take on medical devices please. Thanks.
Q: As this is likely my last missive this year; I wish you all at 5i the best for this Holiday Season and may you all prosper in 2016. What are your views on CXV? Many thanks again. Henry
Q: Good morning team, Are we to assume that next report will be good based on their news today? Would this news give you confidence to average down?
Thank you!
Thank you!
Q: Is there no deadline for filing interim F. Statements for this classification of Co.? They just don't seem to play by the usual rules! Thank you.
Q: What do you think about MSL for a 10 year hold? I have a small position and I'm wondering if its worth holding long term. Thanks, Neil
Q: Your take on latest numbers reported and where this company is headed.Thank You
garry
garry
Q: My healthcare exposure is very lean with CVS as my only current holding. What names interest you that would warrant further research on my part? It will likely be held in a TFSA. I'm looking for a moderate growth/risk name at this time.
Thanks!
Thanks!
Q: Could you comment please? Thanks.
Q: Do you like TH? Did management sandbag buyers of its units at $2.40?
Q: Can you provide update. Can't believe the vol.
Q: Your views as to the growth and outlook of this company. tks
Q: I've been a long-term owner of Allergan. The potential deal with Pfizer indicates that 11.3 shares of PFE will be granted for every 1 share of AGN. Looking at the closing prices of each company on Friday Nov 4th, AGN closed at $316.50 and PFE closed at $32.80. At 11.3 shares of PFE per AGN, this currently values AGN at $360.80.
In your opinion, why are the AGN shares not trading around the value of the deal? Is there significant pessimism about the deal? Are the targets for PFE shares significantly lower over the next year?
Seems to me this is kind of a "back the truck up" opportunity...
Thanks!
In your opinion, why are the AGN shares not trading around the value of the deal? Is there significant pessimism about the deal? Are the targets for PFE shares significantly lower over the next year?
Seems to me this is kind of a "back the truck up" opportunity...
Thanks!
Q: I have held SPDR Health Care E.T.F. XLV-N for some time. At this time, it is a hold or sell? Going forward for a longer term horizon, Is there another US ETF that I should take a position in?
Q: Any thoughts about the potential here as it is trading for it's cash value with no debt. Thanks
Q: seems like pli is selling on good news? isn't switching clinical trials to a placebo controlled one a higher quality trial? so why the sell off? is it time to add or wait for this to shake out?
Thanks Peter.
Thanks Peter.
Q: Jean-Coutu has fell 15% since yesterday because the governement will effectively make generic drugs cheaper. This is a huge part of Jean-Coutu's business. Could you discuss the impact on the company? (1) Considering the extent of the impact on their future revenues, how much do you think the stock could contract? Technically, there is some support at 15$. (2) If you were close to retirement, who you buy? I like the nature of the business, 2.5% dividend and the dividend growth history. However I don't want to see the stock fall another 15%. (3) Insiders were buying a lot at 19$ very recently, they must have known about the possibility of this happenning? Thank you team.
http://www.bloomberg.com/news/articles/2015-11-26/jean-coutu-slumps-most-in-7-years-on-proposed-quebec-drug-reform
http://www.bloomberg.com/news/articles/2015-11-26/jean-coutu-slumps-most-in-7-years-on-proposed-quebec-drug-reform
Q: Peter and team: Currently holding Phm and GUD, (3%) of my portfolio.. I have thought of adding Concordia CXR, but am open to other names. Any suggestions?